Reframe Daily: Psoriasis pill rivals shots; allergy med relieves ER vertigo fast; some can skip breast-cancer radiation

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: In new trials, a common allergy-medicine combo eased severe vertigo quickly; a phase-3 pill worked as well as psoriasis shots; many breast-cancer patients kept 10-year survival without chest-wall radiation; a kidney drug slowed decline in IgA disease; and a nasal H5N1 vaccine built broad defenses in people.

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Personal shares from Christin here →
http://christin.substack.com/

Good news: A simple treatment helped people with sudden, severe vertigo feel better faster using medicines that are already on the shelf.

Diphenhydramine, Sodium Bicarbonate, or Combination Therapy for Acute Peripheral Vertigo in the Emergency Department

Market readiness: 🙂🙂🙂🙂🙂 (uses widely available generics; clinicians can apply off‑label now while guidelines catch up). 

Good news: A first‑in‑class oral IL‑23–receptor blocker cleared skin for many people with moderate‑to‑severe psoriasis in a late‑stage trial—offering a pill alternative to injections.

Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents

Market readiness: 🙂🙂🙂🙂 (positive phase 3 data; not FDA‑approved yet but on a clear regulatory path). 

Good news: Many women with early, “intermediate‑risk” breast cancer who had a mastectomy may safely skip chest‑wall radiation without harming 10‑year survival—fewer side effects and trips for treatment.

Ten‑Year Survival after Postmastectomy Chest‑Wall Irradiation in Breast Cancer

Market readiness: 🙂🙂🙂🙂 (practice‑changing phase 3 evidence; adoption likely via clinician judgment and upcoming guideline updates). 

Good news: A targeted biologic for IgA nephropathy slowed kidney damage and lowered urine protein in a phase 3 trial—promising progress toward delaying dialysis.

Atacicept in IgA Nephropathy

Market readiness: 🙂🙂🙂🙂 (late‑stage data; not yet approved in the US). 

Good news: An intranasal H5N1 flu vaccine safely primed strong, broad immune responses (with a later IM boost), hinting at better protection where flu first enters—the nose.

An intranasal adjuvanted, recombinant influenza A/H5 vaccine primes against diverse H5N1 clades: a phase I trial

Market readiness: 🙂🙂 (early phase 1; larger efficacy trials still needed). Thank you for taking the time to take care of yourself and your loved ones.